Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Transcription factor-based biosensors for screening and dynamic regulation

  • Tellechea-Luzardo, Jonathan
  • Stiebritz, Martin T.
  • Carbonell, Pablo|||0000-0002-0993-5625
[EN] Advances in synthetic biology and genetic engineering are bringing into the spotlight a wide range of bio-based applications that demand better sensing and control of biological behaviours. Transcription factor (TF)-based biosensors are promising tools that can be used to detect several types of chemical compounds and elicit a response according to the desired application. However, the wider use of this type of device is still hindered by several challenges, which can be addressed by increasing the current metabolite-activated transcription factor knowledge base, developing better methods to identify new transcription factors, and improving the overall workflow for the design of novel biosensor circuits. These improvements are particularly important in the bioproduction field, where researchers need better biosensor-based approaches for screening production-strains and precise dynamic regulation strategies. In this work, we summarize what is currently known about transcription factor-based biosensors, discuss recent experimental and computational approaches targeted at their modification and improvement, and suggest possible future research directions based on two applications: bioproduction screening and dynamic regulation of genetic circuits., JT-L was supported by European Union Marie Sklodowska-Curie Action Individual Postdoctoral Fellowship (Grant agreement ID: 101062593). JT-L was supported by the Next-Generation EU (NGEU) fund through the Spanish Recovery, Transformation and Resilience Plan via a Margarita Salas personal grant from the Spanish Ministry of Universities (UNI/551/2021). MS was supported by the NextGeneration EU (NGEU) fund through the Spanish Recovery, Transformation and Resilience Plan via a María Zambrano personal grant from the Spanish Ministry of Universities (UNI/551/2021). PC acknowledges MCIN/AEI/10.13039/501100011033 funding through PID2020-117271RB-C2 (BIODYNAMICS). PC was supported by the Spanish Ministry of Universities (UNI/551/2021), grant number UP 2021-036 funded by European Union - Next-generation EU. This research received financial support from Generalitat Valenciana through grant CIAICO/2021/159 (SmartBioFab). PC acknowledges MCIN/AEI/10.13039/501100011033 and NextGenerationEU/PRTR funding through grant TED 2021-131049 B-I00 (BioEcoDBTL). PC acknowledges MCIN/AEI/10.13039/501100011033 funding through grant PID 2021-127888NA-I00 (COMPSYNBIO).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Enhancing the performance of GPU acceleration in virtual environments: Thoroughly benchmarking the rigidity of mediated device passthrough

  • Prades, Javier|||0000-0003-3349-2200
  • Silla, Federico|||0000-0002-6435-1200
  • Reaño, Carlos
[EN] Virtualization has been the key element for the growth of cloud computing. Historically, GPUs have been complex devices to virtualize efficiently. The mediated passthrough mechanism is usually leveraged. However, it implies a rigid association between the virtual domain and the virtual GPU, which impairs overall system GPU performance. In this paper we propose the use of Network GPGPU system (NGS) to improve the performance of GPUs in virtual domains. Our proposal is compared to NVIDIA vGPU, the most widely used mechanism for virtualizing CUDA-enabled GPUs today. Results show throughput benefits of approximately 20%, speedup of up to 28% in the execution time of the applications, improved overall GPU utilization (over 85%), and lower energy consumption per job (up to 15.34%)., Javier Prades was supported by Margarita Salas Postdoctoral Fellowship (UP2021-036) from Universitat Politecnica de Valencia Funded by Ministerio de Universidades and the European Union-Next Generation EU.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Targeting the senescent surfaceome through DPP4 antibody-functionalized nanoparticles. An application to cancer therapy

  • Escriche-Navarro, Blanca
  • Garrido-García, Eva María
  • Escudero-Noguera, Andrea|||0000-0003-2670-6127
  • Montoya-Méndez. Isabel |||0009-0003-7755-4853
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Due to the heterogeneity of the senescent phenotype and the lack of a universal biomarker of senescence, the targeting of senescent cells is still an unresolved challenge, and the elimination of senescent cells using specific drugs (senolytics) is still limited in clinical use due to the off-target effects and associated toxicities of current therapeutic strategies. In this study, the induction of senescence in human melanoma cells by palbociclib is found to lead to a senescent phenotype characterized by overexpression of the membrane protein dipeptidyl peptidase 4 (DPP4), previously identified only in ageing contexts. Based on this discovery, a nanoparticle targeting DPP4 overexpression in the senescent surfaceome is designed, synthesized, and characterized to target senescent cancer cells. The nanoparticle based on mesoporous silica is loaded with the senolytic navitoclax, coated with disulfide-containing poly(ethylene glycol) to generate a redox-sensitive gatekeeper (S-S-PEG), and functionalized with an antibody against the DPP4 protein. The ability of the nanoparticles to effectively detect and eliminate senescent cells was confirmed in vitro and in vivo using a mouse model of palbociclib-induced senescent in melanoma. The DPP4-targeted nanoparticle effectively reduces tumor growth and selectively removes senescent cells. Taken together, this study highlights the potential of surfaceome-targeted nanoparticles, as a clinically relevant strategy for improving senolytic therapies., This research was supported by projects PID2021-128141OB-C22 and PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/10.13039/501100011033/and by European Regional Development Fund-A way of doing Europe and by the ERC Advanced Grant Edison (101052997) . This study was also supported by Generalitat Valenciana (CIPROM/2021/007) . This research was supported by CIBER (CB06/01/2012) , Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovacion. B.E-N. is grateful to the Instituto de Salud Carlos III (ISCIII) for the grant through the project "IFI19/00026", co-funded by the European Union and the company Senolytic Therapeutics S.L for the support. E.G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her "Margarita Salas" postdoctoral grant (UP2021-036) .
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Nanodevice-Mediated Immune Cell Recruitment: Targeting Senescent Cells via MMP-3-Responsive CXCL12-Coated Nanoparticles

  • Escriche-Navarro, Blanca
  • Labernadie, Anna
  • Garrido-García, Eva María
  • Clara-Trujillo, Sandra|||0000-0002-6455-2993
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Senescent cells are involved in age-related disorders in different organs and are therapeutic targets for fibrotic and chronic pathologies. Immune-modulating agents, able to enhance senescent cell detection and elimination by endogenous immune cells, have emerged as pharmacological strategies. We report herein a nanoparticle for immune cell-mediated senolytic therapy designed to recruit immune cells in response to specific enzymatic matrix metalloproteinase-3 (MMP-3) activity in the senescence-associated secretory phenotype. For this, mesoporous silica nanoparticles (MSNs) are coated with a peptide substrate of the metalloproteinase MMP-3, and the peptide is decorated with chemokine CXCL12 that enhances immune cell recruitment (NPs@CXCL12). Controlled release studies confirmed the progressive and specific release of CXCL12 in the presence of MMP-3. The ability of immune cell recruitment in response to a senescent microenvironment (senescent WI-38 fibroblasts) is confirmed by Transwell migration assays with green fluorescent Jurkat T-cells, showing NPs@CXCL12 has an enhanced chemotaxis effect toward senescent cells compared to free CXCL12 (2-fold). Moreover, the cytotoxic capacity of human primary natural killer (NK) cells over senescent WI-38 is also confirmed, and their migration trajectories in response to NPs@CXCL12 or free CXCL12 are monitored by using a microfluidic device. Results confirm the ability of NPs@CXCL12 to generate a chemotactic gradient able to attract NK cells. When compared with free CXCL12, the NPs@CXCL12 system showed a reduction of up to 15.56% in the population of NK cells migrating toward free CXCL12 under competitive conditions. This study demonstrates the potential of designing nanoparticles to recruit immune cells under specific responses to eliminate senescent cells. Results confirm that NPs@CXCL12 can effectively establish a chemotactic gradient to attract NK cells., This research was supported by projects PID2021-128141OB-C22 and PID2021-126304OB-C41 funded by MCIN/AEI/10.13039/501100011033/and by the European Regional Development FundyA way of doing Europe. This study was also supported by the ERC Advanced Grant Edison (101052997), the Generalitat Valenciana (CIPROM/2021/007) and CIBER (CB06/01/2012), Instituto de Salud Carlos III, and Ministerio de Ciencia e Innovacion. A.L. is grateful to the RYC2020/029736/I grant and PID2021-125212OA-I00 project funded by MCIN. B.E-N. is grateful to the Instituto de Salud Carlos III (ISCIII) for the grant through the project "IFI19/00026", cofunded by the European Union and the company Senolytic Therapeutics S.L. for the support. E.G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her "Margarita Salas" postdoctoral grant (UP2021-036).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Molecular Cages as Probes in Indicator Displacement Assays: The Case of Scopolamine Detection

  • Montà-González, Giovanni|||0000-0002-0739-9937
  • Garrido-García, Eva María
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Martí-Centelles, Vicente|||0000-0002-9142-9392
  • Climent Terol, Estela
  • Vicent, Cristian
[EN] A study of the Pd-based molecular cage C1 host-guest properties against fluorescein and the drug scopolamine is reported. C1 forms an interpenetrated structure C12 in the presence of >= 40% water in H2O/DMSO solvent mixtures. The presence of fluorescein (FL) induces the disassembly of the C12 structure to form the [FL2 subset of C1] complex. Moreover, the addition of scopolamine (SCOP, a drug typically involved in drug-facilitated sexual assaults) to [FL2 subset of C1] results in fluorescein release and the formation of [SCOP subset of C12], obtaining a fluorescence signal proportional to the concentration of scopolamine with a limit of detection as low as 59.4 mu g mL-1. A good selectivity for scopolamine against other drugs such as MDMA, cocaine, GBL, and ketamine is observed. This is the first scopolamine detection method described to date using a molecular cage and one of the very few examples of the use of cages in indicator displacement assays. Similar concepts could be applied to the design of other molecular cage-based sensors for the detection of target analytes., V.M.-C. acknowledges the financial support from projects ESGENT/2024/001 and CIDEGENT/2020/031, both funded by the Generalitat Valenciana, Project PID2024-157188OB-I00 funded by MICIU/AEI/10.13039/501100011033 y FEDER A way to make Europe, Project PID2020-113256RA-I00 funded by MICIU/AEI/10.13039/501100011033, and Project CNS2023-144879 funded by MICIU/AEI/10.13039/501100011033 and European Union NextGenerationEU/PRTR. R.M.- M. acknowledges the financial support from Project PROMETEO CIPROM/2021/007 from the Generalitat Valenciana, project PID2024-155683OB-C41 funded by MICIU/AEI/10.13039/501100011033 y FEDER A way to make Europe, and project PID2021-126304OB-C41 funded by MICIU/AEI/10.13039/501100011033/and FEDER A way to make Europe. This research was supported by CIBER Consorcio Centro de Investigacion Biomedica en Red (CB06/01/2012), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovacion. E.C. thanks the Instituto de Salud Carlos III (Miguel Servet 2023 CP23/00086) and E.G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her "Margarita Salas" postdoctoral grant (UP2021-036). The authors would like to acknowledge the Rigel computing system of the Universitat Politecnica de Valencia for providing the computational resources necessary for this study. The authors thank the U26 facility of ICTS "NANBIOSIS" and the nuclear magnetic resonance facility of Fundacion de la Comunidad Valenciana Centro de Investigacion Principe Felipe (CIPF) for NMR experiments. The authors thank "Servei Central d'Instrumentacio Cientifica (SCIC)" at Universitat Jaume I for mass spectrometry measurements.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Targeted Delivery of the Pan-Inflammasome Inhibitor MM01 as an Alternative Approach to Acute Lung Injury Therapy

  • García-Fernández, Alba|||0000-0002-8416-1674
  • Garrido-García, Eva María
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Sancho, Mónica
  • Bisbal, Viviana
  • Orzáez, Mar
[EN] Acute lung injury (ALI) is a severe pulmonary disorder responsible for high percentage of mortality and morbidity in intensive care unit patients. Current treatments are ineffective, so the development of efficient and specific therapies is an unmet medical need. The activation of NLPR3 inflammasome during ALI produces the release of proinflammatory factors and pyroptosis, a proinflammatory form of cell death that contributes to lung damage spreading. Herein, it is demonstrated that modulating inflammasome activation through inhibition of ASC oligomerization by the recently described MM01 compound can be an alternative pharmacotherapy against ALI. Besides, the added efficacy of using a drug delivery nanosystem designed to target the inflamed lungs is determined. The MM01 drug is incorporated into mesoporous silica nanoparticles capped with a peptide (TNFR-MM01-MSNs) to target tumor necrosis factor receptor-1 (TNFR-1) to proinflammatory macrophages. The prepared nanoparticles can deliver the cargo in a controlled manner after the preferential uptake by proinflammatory macrophages and exhibit anti-inflammatory activity. Finally, the therapeutic effect of MM01 free or nanoparticulated to inhibit inflammatory response and lung injury is successfully demonstrated in lipopolysaccharide-mouse model of ALI. The results suggest the potential of pan-inflammasome inhibitors as candidates for ALI therapy and the use of nanoparticles for targeted lung delivery., This research was supported by Project Nos. PID2021-126304OB-C41, PID2021-128141OB-C22, and PID2020-115048RB-I00 funded by MCIN/AEI/10.13039/501100011033 and by European Regional Development Fund - A way of doing Europe. The authors also thank Generalitat Valenciana (PROMETEO Project CIPROM/2021/007 and PROMETEO 2019/065) for support. E.G. is grateful to the Spanish MIU and European Union-Next Generation EU for her "Margarita Salas" postdoctoral grant (UP2021-036). The authors would also like to thank Animal Facilities from Centro de Investigacion Principe Felipe for its support in the animal research and procedures, and I. Borred and J. Forteza from Instituto Valenciano de Patologia for its technical support in the histopathology analysis. The authors thank for the use of Biorender.com in the figures and graphical abstract.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

A navitoclax-loaded nanodevice targeting matrix metalloproteinase-3 for the selective elimination of senescent cells

  • Escriche-Navarro, Blanca
  • Garrido-García, Eva María
  • Sancenón Galarza, Félix|||0000-0002-5205-7135
  • García-Fernández, Alba|||0000-0002-8416-1674
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Cellular senescence is implicated in the occurrence and progression of multiple age-related disorders. In this context, the selective elimination of senescent cells, senolysis, has emerged as an effective therapeu- tic strategy. However, the heterogeneous senescent phenotype hinders the discovery of a universal and robust senescence biomarker that limits the effective of senolytic with off-target toxic effects. Therefore, the development of more selective strategies represents a promising approach to increase the specificity of senolytic therapy. In this study, we have developed an innovative nanodevice for the selective elimi- nation of senescent cells (SCs) based on the specific enzymatic activity of the senescent secretome. The results revealed that when senescence is induced in proliferating WI-38 by ionizing radiation (IR), the cells secrete high levels of matrix metalloproteinase-3 (MMP-3). Based on this result, mesoporous silica nanoparticles (MSNs) were loaded with the senolytic navitoclax (Nav) and coated with a specific peptide which is substrate of MMP-3 (NPs(Nav)@MMP-3). Studies in cells confirmed the preferential release of cargo in IR-induced senescent cells compared to proliferating cells, depending on MMP-3 levels. More- over, treatment with NPs(Nav)@MMP-3 induced a selective decrease in the viability of SCs as well as a protective effect on non-proliferating cells. These results demonstrate the potential use of NPs to develop enhanced senolytic therapies based on specific enzymatic activity in the senescent microenvironment, with potential clinical relevance., This research was supported by projects PID2021-126304OBC41 and PID2021-128141OB-C22 funded by MCIN/ AEI /10.13039/501100011033/ and by European Regional Development Fund - A way of doing Europe. This study was also supported by Generalitat Valenciana (CIPROM/2021/007). This research was supported by CIBER (CB06/01/2012), Instituto de Salud Carlos III and Ministerio de Ciencia e Innovación. This work was also supported by the European Research Council (ERC) via Advanced Grant (101052997, EDISON). B.E-N. is grateful to the Instituto de Salud Carlos III (ISCIII) for the grant through the project IFI19/00026 , co-funded by the European Union and the company Senolytic Therapeutics S.L for the support. E.G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her Margarita Salas postdoctoral grant (UP2021-036).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Smartphone-assisted lateral flow nanosensor for the selective detection of GHB in urine

  • Garrido-García, Eva María
  • Hernández-Sigüenza, Guillermo|||0000-0002-2075-3005
  • Mollá-Guerola, Lara|||0009-0009-2387-9816
  • López-Lima, Rocío|||0009-0007-8121-8085
  • Ortiz-Gómez, Eduardo|||0009-0005-5778-9158
  • Montà-González, Giovanni|||0000-0002-0739-9937
  • Hernández-Montoto, Andy|||0000-0001-5623-9836
  • Martí-Centelles, Vicente|||0000-0002-9142-9392
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
  • Climent Terol, Estela
  • Gaviña, Pablo
[EN] We report a rapid test strip based on mesoporous silica nanoparticles functionalized with a specific GABA(B) receptor agonist to selectively detect gamma-hydroxybutyric acid (GHB) in urine samples. The sensing mechanism involves rhodamine B-loaded MCM-41 silica nanoparticles whose pores are capped with a GABA-derived ligand (baclofen) acting as a gatekeeper via supramolecular interactions with the GABA(B) receptor protein. In the presence of GHB, competitive binding produces GABA(B) receptor protein displacement, leading to pore opening and fluorophore release, which is detected via fluorescence readout. The nanosensor demonstrated high sensitivity, with a limit of detection (LOD) of 168 mu M in buffer solution and 41 mu M in diluted urine. Selectivity assays showed highly specific sensor response over common drugs such as cocaine, morphine, MDMA, heroin, scopolamine, 1,4-butenediol (1,4-BD), gamma-aminobutyric acid (GABA), and gamma-butyrolactone (GBL). The sensing material was also incorporated into a lateral flow assay (LFA) platform with a smartphone-assisted fluorescence readout, providing a rapid, portable, and low-cost analysis of GHB. The resulting test strip exhibited high sensitivity, with a LOD of 0.28 mu M in diluted urine, which is low enough to clearly distinguish between physiological endogenous GHB levels (similar to 96 mu M) and exogenous intake within only 1 min, a crucial requirement in forensic and clinical toxicology. This portable, cost-effective method holds strong potential for on-site forensic and clinical GHB screening., This work was financially supported by the Universitat Politecnica de Valencia (PAID-06-23) and by the Spanish Ministry of Science and Innovation through projects PID2021-126304OB-C41 and PID2024-155683OB-C41 (MICIU/AEI/10.13039/501100011033), co-funded by the European Regional Development Fund (FEDER, "A Way of Making Europe"). This study also forms part of the Advanced Materials Program (MFA/2022/053) and was supported by MCIN with funding from the European Union-Next Generation EU (PRTR-C17.I1) and by Generalitat Valenciana. This study was also supported by Generalitat Valenciana (CIPROM/2021/007). E. G. is grateful to the Spanish MIU and European Union-Next Regeneration EU for her "Margarita Salas" postdoctoral grant(UP2021-036).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

SelenzymeRF: updated enzyme suggestion software for unbalanced biochemical reactions

  • Stoney, Ruth A.
  • Hanko, Erik K. R.
  • Breitling, Rainer
  • Carbonell, Pablo|||0000-0002-0993-5625
[EN] Selenzyme is a retrobiosynthesis tool that suggests candidate enzymes for user query reactions. Enzyme suggestions are based on identical reactions, as well as similar reactions, since enzymes are often capable of promiscuous substrate binding. Selenzyme is a user-friendly, widely used web-tool for ranking enzymes based on reaction similarity and additional features, including the phylogenetic distance between the source species of the enzyme and the intended host. While Selenzyme has proved invaluable in assisting with enzyme selection for known reactions, as well as many novel or orphan reactions, weaknesses have been exposed in its ability to rank functionally related enzymes. Within this update, we introduce a new reaction similarity scoring algorithm, which is used in conjunction with the previous similarity calculation, to improve the accuracy of enzyme suggestions based on non-identical similar reactions, across a range of EC reaction classes. This allows enzymes to be suggested for reactions not found within the database, even if the reaction is unbalanced. A database update was also carried out, to ensure that reaction and enzyme knowledge remains current. This update can be accessed at http://selenzymeRF.synbiochem.co.uk/., This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement 814408 SHIKIFACTORY100-Modular cell factories for the production of 100 compounds from the shikimate pathway.We acknowledge funding from the Biotechnology and Biological Sciences Research Council (BBSRC) under grant BB/M017702/1 "Centre for synthetic biology of fine and speciality chemicals (SYNBIOCHEM)". Pablo Carbonell was supported by the Spanish Ministry of Universities (UNI/551/2021), grant number UP2021-036 funded by European Union-Next generation EU.Pablo Carbonell acknowledges funding from Generalitat Valenciana through grant CIAICO/2021/159 (SmartBioFab). Pablo Carbonell acknowledges MCIN/AEI/10.13039/ 501100011033 and NextGenerationEU/ PRTR funding through grant TED2021-131049B-I00 (BioEcoDBTL).
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

NGS: A network GPGPU system for orchestrating remote and virtual accelerators

  • Prades, Javier|||0000-0003-3349-2200
  • Silla, Federico|||0000-0002-6435-1200
  • Reaño, Carlos
[EN] In General-Purpose computing on Graphics Processing Unit (GPGPU), the use of CPUs is combined with that of GPUs. CPUs are used for sequential code, while GPUs are used for parallel code. GPGPU has been enabled by two key factors: (i) the massively parallel architecture of GPUs, which allows thousands of single cores to run parallel code; and (ii) the development of platforms, such as CUDA, that simplify implementing code for GPUs. GPGPU has established itself as the standard computing system in most computing fields due to the great improvements it brings. However, its use is not without problems, such as GPU underutilization, high cost, power consumption, etc. In this paper we present NGS (Network GPGPU System) to address the underutilization of GPUs in computing centers. NGS orchestrates the concurrent access to GPGPU resources from different nodes of the cluster by leveraging the remote GPU virtualization mechanism and the NVML library by NVIDIA. In this way, NGS enables different nodes of the cluster to access remote GPUs as if they were local at the same time that this access is guaranteed to be carried out without collisions. The main novelty is that NGS offers a global and standard solution independent of the computing environment used. Experimental results show up to 4x improvements compared to popular approaches., Javier Prades was supported by Margarita Salas Postdoctoral Fellowship (UP2021-036) from Universitat Politecnica de Valencia Funded by Ministerio de Universidades and the European Union-Next Generation EU.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-Term Feeding of Dairy Goats with 40% Artichoke by-Product Silage Preserves Milk Yield, Nutritional Composition and Animal Health Status

  • Monllor, Paula|||0000-0002-8343-6058
  • Zemzmi, Jihed|||0000-0001-7030-2707
  • Muelas, Raquel
  • Roca, Amparo|||0000-0001-7502-9420
  • Sendra Nadal, Esther|||0000-0002-6830-1956
  • Romero, Gema|||0000-0001-9219-1542
  • Díaz, José Ramón
The rational use of agriculture and agro-industrial by-products in ruminant nutrition contributes to greater respect for the environment in addition to a better final product quality. Artichoke crops are widespread in the Mediterranean region but mostly not properly valued. Previous studies carried out with artichoke by-product silage at 25, 40 and 60% inclusion in dairy goat feed for one month showed that 40% inclusion would be a good option without any harm to milk yield and composition or animal health status. Therefore, it is worth studying the effect of feeding animals with 40% artichoke by-product silage during a full lactation period. No negative effects were observed on animal performances and productivity, allowing us to reduce agroindustry wastes and offering a long-term preserved by-product that promotes a sustainable circular economy and the production of animal products with high nutritional value, like goat milk. The aim of this work is to study the effect of 40% inclusion of artichoke by-product silage (AB) in dairy goat diets on milk yield, composition and animal health status during a full lactation period compared to an isoenergetic and isoproteic mixed ration based on alfalfa hay and a cereal and legume mixture. Milk yield was not affected by the dietary treatments, and neither was body weight. AB treatment reduced whey protein (0.38 vs. 0.42%, p < 0.05) and milk urea concentrations (687 vs. 773 mg/L, respectively, p < 0.001), and did not affect total true protein (3.22 vs. 3.24% p.